Stat Profile Prime Plus® Analyzer
- Dec. 27, 2018
-- ova Biomedical has been awarded a multi-year group purchasing agreement for critical care blood gas analyzers from Premier. This agreement provides Premier members access to Nova's new Stat Profile Prime Plus®
critical care blood gas analyzer. Prime Plus features maintenance-
free sensor technology to provide 20 essential critical care tests including BUN, Creatinine, Ionized Magnesium, blood gases, electrolytes, metabolites, hematology, and co-oximetry. Prime Plus also provides new and patented, non-lysing whole blood co-oximetry technology, along with automated quality control (QC), powerful data management, bidirectional connectivity, and extensive cybersecurity protection.
Effective October 18, 2018, the current agreement now allows Premier members, at their discretion, to take advantage of special, pre-negotiated pricing and terms for Prime Plus analyzers and consumables in addition to Nova's 10-test Prime analyzers.
"We are pleased that Premier has awarded a group purchasing agreement to our innovative, maintenance-
free Prime Plus," said John Britt, Director of Corporate Accounts for Nova. "This agreement allows Premier members access to the entire Stat Profile Prime platform including its new flagship analyzer, Prime Plus. Prime Plus introduces innovative technology that expands critical care testing with unique assays and eliminates sensor and co-oximeter maintenance, all of which improves uptime and reliability while reducing costs. Prime Plus represents the latest in critical care testing technology and further demonstrates Nova's leadership and history of innovation."
Prime Plus incorporates Nova's innovative, maintenance-
free sensor technology with individual MicroSensor cards, calibrator cartridges, and quality control cartridges. This design eliminates sensor and co-oximeter maintenance, improves analyzer uptime, and reduces testing costs for the compact and easy-to-use Prime Plus.
Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,000 U.S. hospitals and 165,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost.About Nova Biomedical
Incorporated in 1976 and based in Waltham, MA, Nova Biomedical is a world leader in the development and manufacturing of state-of-the-
art, whole blood, point-of-care and critical care analyzers, as well as providing the biotechnology industry with the most advanced instruments for cell culture monitoring. Nova is one of the fastest growing in vitro diagnostic companies in the world. Nova's biosensor technology is incorporated in products ranging from handheld meters for glucose self- and point-of-care testing to critical care whole blood analyzers designed for rapid measurement of over 20 analytes. Nova's biotechnology-
specific BioProfile line has pioneered comprehensive cell culture testing, providing over 16 critical cell culture tests with 12 unique instrument offerings for broad range of cell culture applications. Nova employs over 1,200 people worldwide and has wholly owned subsidiaries located in Brazil, Canada, France, Germany, Great Britain, Italy, Japan, Spain, Switzerland, and Taiwan.
Visit Nova Biomedical at http://www.novabio.us